DDAVP TABLETS 0.1MG

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

DESMOPRESSIN ACETATE

Saadav alates:

FERRING INC

ATC kood:

H01BA02

INN (Rahvusvaheline Nimetus):

DESMOPRESSIN

Annus:

0.1MG

Ravimvorm:

TABLET

Koostis:

DESMOPRESSIN ACETATE 0.1MG

Manustamisviis:

ORAL

Ühikuid pakis:

30

Retsepti tüüp:

Prescription

Terapeutiline ala:

PITUITARY

Toote kokkuvõte:

Active ingredient group (AIG) number: 0112050005; AHFS:

Volitamisolek:

CANCELLED POST MARKET

Loa andmise kuupäev:

2022-05-31

Toote omadused

_DDAVP Tablets 0.1 mg and 0.2 mg _
_Template Date: January 2010 _
_Page 1 of 29 _
PRODUCT MONOGRAPH
PR
DDAVP
® TABLETS
Desmopressin Acetate
0.1 mg and 0.2 mg Tablets
Antidiuretic
Ferring Inc.
200 Yorkland Boulevard
Suite 500
North York, Ontario
M2J 5C1
Date of Revision:
DECEMBER 17, 2015.
CONTROL NUMBER: 187744
_DDAVP Tablets 0.1 mg and 0.2 mg _
_Template Date: January 2010 _
_Page 2 of 29 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
...........................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II: SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................14
CLINICAL TRIALS
............................................................................................